The tissue inhibitor of metalloproteinases-2 (TIMP-2) is known to antagonize matrix metalloproteinase activity and to suppress tumor growth, angiogenesis, invasion and metastasis. We analysed the methylation status of the CpG island in the TIMP-2 promoter region by methylation-specific polymerase chain reaction (MSP) in hematopoietic cell lines. TIMP-2 promoter hypermethylation in the lymphoma cell line Raji and the leukemia cell line KG1a was associated with transcriptional repression. Treatment with the demethylating agent 5-aza-2 0 -deoxycytidine resulted in TIMP-2 upregulation in both cell lines. TIMP-2 was expressed in the cell lines HL60, U266 and XG1, which carry an unmethylated promoter region. MSP analysis of primary patient samples revealed aberrant methylation of TIMP-2 in 33/90 (36.7%) cases of non-Hodgkin's lymphoma (NHL), but not in normal peripheral blood lymphocytes as well as in nonmalignant bone marrow and lymph nodes. The frequency of TIMP-2 methylation was slightly higher in aggressive NHL subtypes compared to those with an indolent subtype (38.6 versus 33.3%). In contrast, TIMP-2 was not hypermethylated in any of the 40 cases of acute myelogenous leukemia examined. We conclude that promoter hypermethylation of TIMP-2 is a novel epigenetic event in the pathogenesis of lymphoid malignancies and may contribute to a more aggressive NHL phenotype.
Introduction
Matrix metalloproteinases (MMPs) are a family of zincdependent endopeptidases, which can synergistically degrade the major components of the extracellular matrix (ECM). The proteolytic activity of MMPs is primarily controlled by four members of the tissue inhibitors of metalloproteinases (TIMP) family. The homeostasis between the activities of MMPs and TIMPs is not only a prerequisite for normal function of an array of physio-pathological processes involving the turnover of ECM, but is also a critical determinant of the invasive potential of many human malignant tumors (Chambers and Matrisian, 1997; Nagase and Woessner, 1999; Brew et al., 2000; Stamenkovic, 2000) . TIMPs have been demonstrated to inhibit tumor growth, invasion and metastasis in experimental models, and these actions have been associated not only with their MMP inhibitory activities but also with antiangiogenic properties (Gomez et al., 1997) .
There is increasing evidence for a role of TIMP-2, which has been mapped to chromosome 17q25, as a tumor-suppressor gene. Overexpression of TIMP-2 in tumor cell lines resulted in decreased invasive potential as well as inhibition of tumor growth and vascularization (Albini et al., 1991; Vergani et al., 2001; Cappabianca et al., 2003) . In a recent study, TIMP-2 has been shown to inhibit angiogenesis in association with downregulation of vascular endothelial growth factor (VEGF) in a breast cancer mouse model (Hajitou et al., 2001) . Abnormal angiogenesis mediated by VEGF is increasingly recognized to play a major role in the development and progression of hematopoietic malignancies (List, 2001 ). Loss of TIMP-2 expression was previously noted in acute leukemia (Janowska-Wieczorek et al., 1999) and B-cell lymphoma cell lines (StetlerStevenson et al., 1997) as well as in several cases of primary non-Hodgkin's lymphoma (NHL) (Kossakowska et al., 1993) .
Deranged DNA methylation patterns leading to genespecific transcriptional silencing in association with promoter hypermethylation have been recognized as a key epigenetic mechanism in carcinogenesis. In addition to genetic alterations, such as mutations or deletions, aberrant regional DNA methylation acts as an alternative mechanism to disrupt tumor-suppressor gene function. A growing list of genes involving fundamental cellular pathways have been demonstrated to harbor dense methylation in normally unmethylated CpG islands near their promoter regions (Esteller et al., 2001 ). This aberrant promoter hypermethylation is the most widely studied epigenetic abnormality in tumorigenesis and is often associated with transcriptional silencing of the affected genes (Baylin and Herman, 2000; Jones and Baylin, 2002) . The binding of protein complexes consisting of methylcytosine-binding proteins, transcriptional corepressors, chromatin remodeling proteins and histone deacetylases to hypermethylated DNA regions result in a transcriptionally repressive chromatin state (Bird, 2002; Herman and Baylin, 2003) .
Methylation-associated silencing of TIMP-3, another member of the TIMP family, has been previously demonstrated in a variety of human solid tumors (Bachman et al., 1999) . Using a genomic screening approach, aberrant hypermethylation of the TIMP-2 gene, which also contains a CpG island within its promoter region (Hammani et al., 1996) , was recently detected in the colorectal cancer cell line RKO (Suzuki et al., 2002) . However, methylation of TIMP-2 was not found commonly in primary colorectal tumors. Owing to the potential role of TIMP-2 function and angiogenesis in the pathogenesis of human hematopoietic malignancies, we investigated whether loss of TIMP-2 expression may be associated with aberrant promoter methylation in acute myelogenous leukemia (AML) and NHL.
Results

TIMP-2 expression in hematopoietic cell lines
We examined TIMP-2 expression in hematopoietic cell lines and normal peripheral mononuclear blood cells (PBMNC) by semiquantitative reverse transcriptasepolymerase chain reaction (RT-PCR) (Figure 1a ). The AML cell line HL60 and the multiple myeloma (MM) cell lines U266 and XG1 as well as normal PBMNC had easily detectable expression of TIMP-2 transcripts. In contrast, the AML cell line KG1a cells showed weak expression, and the Burkitt's lymphoma cell line Raji had undetectable transcript levels. To explore a possible association between promoter hypermethylation and TIMP-2 expression, we incubated KG1a and Raji cells with the demethylating agent 5-aza-2 0 -deoxycytidine (DAC) (1.0 mM) for 96 h. As shown in Figure 1a , DAC effectively restored TIMP-2 expression in both cell lines.
TIMP-2 immunostaining
In order to examine TIMP-2 expression on the protein level, immunostaining of TIMP-2 was performed on cytospin preparations of the cell lines Raji and HL-60. In Raji cells, which lack mRNA expression, there was no staining signal. In contrast, HL-60 cells, which show abundant expression at the RNA level, showed staining signals in the cytoplasm and on the cellular membrane (Figure 1b) . Thus, in those cell lines, mRNA transcription was shown to correlate with protein expression.
Bisulfite sequencing of the TIMP-2 promoter region
To determine whether methylation of the TIMP-2 promoter region was responsible for the loss of expression of this gene, we examined the methylation pattern of the TIMP-2 promoter region in the cell lines Raji, HL60 and KG1a as well as in normal PBMNC by sodium bisulfite sequencing of individual alleles. The proximal promoter and 5 0 exon 1 of this gene lie in a CpG island shown in Figure 2a . Genomic bisulfite sequencing revealed that HL60 cells and PBMNC, which show abundant expression of TIMP-2, were almost completely unmethylated with only methylation of a few individual CpG sites on a few alleles (Figure 2b ). In contrast, KG1a cells, which express barely detectable TIMP-2, had a heterogeneous methylation pattern, with methylation of several CpG sites on every allele. Finally, every allele examined in the TIMP-2-negative Raji cell lines harbored dense and nearly complete methylation throughout the entire region surrounding the transcription start site. These sequencing results suggest that methylation in the region of the transcriptional start site correlates with diminished or absent expression of TIMP-2. 
TIMP-2 methylation in primary patient samples
Having established that TIMP-2 promoter hypermethylation is associated with decreased expression in hematopoietic cell lines, and that the presence of methylation in this region examined correlated with loss of TIMP-2 mRNA, we analyzed the TIMP-2 methylation status of primary patient samples by MSP. Representative MSP results are shown in Figure 3b . We detected hypermethylation of the TIMP-2 promoter region in 33/90 NHL patients (36.7%), while there was no aberrant TIMP-2 methylation in 40 AML samples. There was a trend towards a higher TIMP-2 hypermethylation frequency in NHL subtypes with an aggressive phenotype compared to those with an indolent phenotype (Table 1) . One unusual feature of the malignant lymphomas with methylation was that TIMP-2 hypermethylation was only found in those NHL samples that originated from peripheral lymph nodes, while all NHL samples from PB or BM were unmethylated (Table 1 ; Po0.0001). While the distribution of NHL subtypes presenting with node involvement compared to PB or BM was somewhat different (the frequency of aggressive NHL subtypes was 51/70 for samples from peripheral lymphatic organs and 6/20 for samples from PB or BM), this discrepancy persisted even for types, such as diffuse large B-cell lymphoma, for which we had both presentations. We additionally analysed autopsy samples from nonmalignant lymph nodes (hilar and mediastinal lymph nodes from three patients) by MSP and found no aberrant TIMP-2 methylation.
Discussion
A variety of fundamental pathways have been previously shown to be disrupted by promoter hypermethylation in lymphomagenesis. These include cell cycle control (p16, p15, p73) (Herman et al., 1997; Corn et al., 1999) , regulation of apoptosis (DAP kinase) (Katzenellenbogen et al., 1999; Rossi et al., 2004) , DNA repair (O 6 -methylguanine-DNA-methyltransferase) (Esteller et al., 2002a) and retinoic acid signaling (cellular retinal-binding protein-1, retinoic acid receptor b) (Esteller et al., 2002b) . It could be demonstrated that multiple genes may be simultaneously affected by aberrant regional hypermethylation in various NHL subtypes (Rossi et al., 2004; Takahashi et al., 2004) .
The current study reveals frequent methylation of the CpG island in the 5 0 region of the TIMP-2 gene in NHL. Previous reports have not demonstrated this event to be clinically relevant in other malignancies. For example, (Suzuki et al., 2002) . A previous study about the genomic structure of the TIMP-2 promoter region suggested that hypermethylation does not play a major role in the regulation of TIMP-2 expression, since no methylation differences were observed between two bladder cancer cell lines which expressed or did not express TIMP-2 (Hammani et al., 1996) . However, in this paper, methylation-sensitive restriction enzyme digestion of DNA followed by Southern blotting was used for methylation analysis which only provides information about a small number of potential CpG sites in a region, and the examination of only one cell line with loss of gene expression may not be reflective of other tumors. It is also possible that the mechanism for inactivation of TIMP-2 differs between bladder cancer and NHL. Another report suggested frequent aberrant methylation of the 5 0 flanking region of the TIMP-2 gene in cervical cancer (Ivanova et al., 2004) . However, hypermethylation could only be detected in a small region upstream the gene promoter, and there was no tight correlation with gene expression in cell lines.
In our study, using bisulfite-conversion-based methods for methylation analysis, we have demonstrated that aberrant hypermethylation in the TIMP-2 promoter region is associated with transcriptional silencing in hematopoietic tumor cell lines. Genomic bisulfite sequencing analysis revealed that transcriptional silencing of TIMP-2 is related to the overall density of DNA methylation around the promoter region. Re-expression of TIMP-2 in association with partial demethylation could be induced by treatment of these cell lines with the demethylating agent DAC. Hypermethylation of TIMP-2 was detected in 36.7% of primary NHL samples and was restricted to tissue specimens from peripheral lymphatic organs. Although there was partial TIMP-2 promoter hypermethylation in the AML cell line KG1a, there was no methylation in 40 cases with AML. Our findings thus reveal a novel epigenetic event in lymphomagenesis, while hypermethylation-associated silencing of TIMP-2 appears to play no relevant role in the pathogenesis of AML.
There have been controversial reports in the literature about the role of TIMP-2 expression in human tumors. High expression levels of TIMP-2 were shown to correlate with better outcome in hepatocellular carcinoma (Giannelli et al., 2002) and breast cancer (Nakopoulou et al., 2002) . However, in squamous cell carcinoma of the tongue, increased TIMP-2 expression was associated with a poorer prognosis (Yoshizaki et al., 2001) . Lack of TIMP-2 expression was reported in several NHL cases, mostly in those with an aggressive phenotype (Kossakowska et al., 1993) . Additionally, it was shown that in B-cell NHL, there is a higher degree of vascularization than in benign lymphadenopathies, and that high-grade lymphomas are characterized by a higher vessel density than those with a low-grade histology (Vacca et al., 1999) . In a simplistic model, it may be hypothesized that hypermethylation-associated silencing of TIMP-2 leads to disruption of the balance between TIMPs and MMPs resulting in enhanced invasive properties of malignant lymphatic cells. However, because of possible interactions between TIMP-2 and growth factors such as VEGF (Hajitou et al., 2001) , silencing of TIMP-2 in tumor cells may additionally result in increased angiogeneic potential.
Recent studies have provided further insight in the molecular mechanism of TIMP-2 action (Fernandez et al., 2003; Seo et al., 2003) . Seo et al. (2003) could show that TIMP-2 inhibition of endothelial cell proliferation is independent of MMP inhibitory activity and is mediated by silencing the receptors for VEGF and fibroblast growth factor-2 (FGF-2). Thus, loss of TIMP-2 function could possibly increase the cells' responsiveness to growth factors such as VEGF and FGF-2 resulting in disturbed endothelial cell proliferation and vessel formation.
The higher TIMP-2 methylation frequency that we observed in aggressive NHL subtypes supports the hypothesis that increased angiogenesis and higher vessel density may be at least in part attributed to loss of TIMP-2 expression. Since TIMP-2 methylation occurred only in NHL samples that originated from peripheral lymphatic organs, but not from PB or BM, it is possible that there may be a selective role for TIMP-2 in regulating the growth of peripheral lymphatic sites in contrast to the BM space. This may also explain the lack of TIMP-2 hypermethylation in the clinical samples from AML patients, which were derived from either PB or BM. In order to further investigate the potential role of TIMP-2 in AML, it would be necessary to analyse the TIMP-2 methylation status in AML cases with extramedullary manifestations.
In summary, we have shown for the first time that aberrant promoter hypermethylation of the TIMP-2 gene is a frequent epigenetic event in NHL. Tumorspecific methylation of TIMP-2 may be a critical step during malignant progression and enhance extramedullary lymphoma growth as well as invasiveness and angiogenesis. Methylation-associated inactivation of TIMP-2 may not only lead to an imbalance between MMPs and naturally occurring inhibitors resulting in enhanced tumor cell survival and invasion but also contribute to increased angiogenesis.
Materials and methods
Patient samples
BM or peripheral blood (PB) samples were obtained during routine clinical assessment of 60 patients (20 NHL, 40 AML) who presented at the University Hospital Aachen. Control BM samples were aspirated from 20 patients with nonmetastatic solid tumors or malignant lymphoma without BM infiltration or hematopoietic dysfunction as part of the routine staging procedures. Informed consent was obtained from all patients following institutional guidelines. Normal PB samples were collected from five healthy volunteers. Mononuclear cells from TIMP-2 hypermethylation in non-Hodgkin's lymphoma O Galm et al PB and BM were separated by density gradient centrifugation prior to analysis. Details of the additional 70 NHL samples have been described previously (Katzenellenbogen et al., 1999; Esteller et al., 2002a) . The distribution of the various NHL subtypes is summarized in Table 2 . Nonmalignant lymph nodes were harvested at autopsy from the chest and the mediastinum of three nonsmoking patients who died without clinical evidence of cancer.
Cell culture and drug treatment
We obtained cell lines HL60, U266 and Raji from the American Type Culture Collection (ATCC; Manassas, VA, USA) and the cell line KG1a from the German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). XG1 cells were kindly provided by PC Heinrich (RWTH Aachen, Germany). Cell lines KG1a and HL60 were routinely cultured in Iscoves's modified Dulbecco's medium (IMDM; Life Technologies, Rockville, MD, USA) with 20% fetal calf serum (FCS; Gemini Bio-Products, Woodland, CA, USA). U266 cells were routinely cultured in RPMI 1640 (Life Technologies, Rockville, MD, USA) with 15% FCS, XG1 cells in IMDM with 10 U/ml interleukin-6 (Roche, Indianapolis, IN, USA) and 20% FCS, and Raji cells in RPMI 1640 with 10% FCS. KG1a and Raji cells were treated with a final concentration of 1.0 mM 5-aza-2 0 -deoxycytidine (DAC; Sigma, St Louis, MO, USA) for 96 h, harvested and subjected to RNA extraction.
RNA isolation and RT-PCR
Total RNA was isolated using a commercially available kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Approximately 3 mg RNA per sample were reverse transcribed with SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For PCR, 1 ml cDNA was amplified using TIMP-2 primers 5 0 -CCC TCC TCG GCA GTG TGT GGG GTC-3 0 (sense, located in exon 3) and 5 0 -GGG ATG TCA GAG CTG GAC CAG TCG AA-3 0 (antisense, located in exon 5) and GAPDH primers 5 0 -GAC CAC AGT CCA TGC CAT CAC-3 0 (sense) and 5 0 -GTC CAC CAC CCT GTT GCT GTA-3 0 (antisense). Reactions were hotstarted at 951C for 5 min and held at 801C before addition of 1.25 U of Taq polymerase (Invitrogen, Carlsbad, CA, USA). Temperature conditions for TIMP-2 were 35 cycles of 951C for 1 min, 581C for 1 min and 721C for 1 min, followed by one cycle of 721C for 5 min, and for GAPDH 23 cycles of 951C for 1 min, 631C for 1 min and 721C for 1 min, followed by one cycle of 721C for 5 min.
Immunostaining for TIMP-2 protein expression in tumor samples
Immunostaining for TIMP-2 was performed using the Envision system (Dako, Carpinteria, CA, USA). Endogenous peroxidase activity was blocked by incubation with 0.03% hydrogen peroxide in methanol for 20 min. Antigen retrieval was accomplished by microwave irradiation. Slides were placed in 10 mM citric acid buffer and then in a microwave oven for 10 min. To block nonspecific protein binding, sections were treated with 10% normal goat serum for 15 min. Monoclonal anti-TIMP-2 antibody (clone 67-4H11; Chemicon, Temecula, CA, USA) was diluted 1 : 100 and incubated overnight at 41C. Slides were treated with Envision labeled polymer reagent for 1 h, and then incubated with 0.02% hydrogen peroxide and 0.6 mM 3,3 0 -diaminobenzidine in phosphate-buffered saline before final counterstaining with hematoxylin.
Sodium bisulfite treatment and MSP
Genomic DNA was isolated from cell lines and primary tissues using standard methods. Approximately 1 mg of DNA was sodium bisulfite-modified and subjected to MSP as described previously (Herman et al., 1996) . MSP primers that specifically recognized unmethylated TIMP-2 sequence were 5 0 -GTA ATA AAA TTG TGG TTT GGT TTA AGT TT-3 0 (sense) and 5 0 -TTC TCT CCT CTT TAT CTC AAA AAC ACA-3 0 (antisense); primers specific for the methylated TIMP-2 sequence were 5 0 -AAT AAA ATT GCG GTT CGG TTT AAG TTC-3 0 (sense) and 5 0 -CTC TCC TCT TTA TCT CGA AAA CGC G-3 0 (antisense). Reactions were hot-started at 951C for 5 min and held at 801C before addition of 1.25 U of Taq polymerase (Sigma, St Louis, MO, USA). Temperature conditions for PCR were as follows: 35 cycles of 951C for 30 s, 581C for 30 s and 721C for 30 s, followed by one cycle of 721C for 5 min. Normal DNA from PB was treated in vitro with SssI methyltransferase (New England Biolabs, Beverly, MA, USA) in order to generate a positive control for methylated alleles of TIMP-2 .
Sodium bisulfite DNA sequencing
Sodium bisulfite-modified DNA was amplified with primers 5 0 -GTT AGT TAT YGG GAG GAG GAG TAG AAA-3 0 (sense) and 5 0 -ACT CAC CCT CCT CAC CTA CCC CRC TC-3 0 (antisense). Reactions were hot-started at 951C for 5 min and held at 801C before addition of 1.25U of Taq polymerase (Sigma, St Louis, MO, USA). Temperature conditions for PCR were as follows: 35 cycles of 951C for 30 s, 581C for 30 s and 721C for 30 s, followed by a final extension of 721C for 5 min. The 247 bp PCR products were purified using a commercially available kit (Qiagen, Valencia, CA, USA), cloned into the TA vector pCR2.1 TOPO (Invitrogen, Carlsbad, CA, USA) and transformed into Escherichia coli according to the manufacturer's recommendations. Plasmid DNA from isolated clones containing the insert was purified using Wizard Plus Minipreps (Promega, Madison, WI, USA) and subjected to automated sequence analysis (ABI automated sequencing).
Statistical analysis
The two-sided Fisher's exact test was used to analyse the correlation between TIMP-2 methylation status and NHL subgroups. 
